These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 33264330

  • 21. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL.
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [Abstract] [Full Text] [Related]

  • 22. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
    Zhu SS, Dong Y, Zhang HF, Wang LM, Xu ZQ, Zhang M, Gan Y, Chen DW, Wang FC, Yan JG, Zhao P.
    Zhonghua Gan Zang Bing Za Zhi; 2019 Aug 20; 27(8):604-609. PubMed ID: 31594077
    [Abstract] [Full Text] [Related]

  • 23. Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon.
    Tamaki N, Kurosaki M, Kusakabe A, Orito E, Joko K, Kojima Y, Kimura H, Uchida Y, Hasebe C, Asahina Y, Izumi N, Japanese Red Cross Hospital Liver Study Group.
    J Viral Hepat; 2017 Aug 20; 24(8):672-678. PubMed ID: 28199034
    [Abstract] [Full Text] [Related]

  • 24. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study.
    Chan HLY, Chan FWS, Hui AJ, Li MKK, Chan KH, Wong GLH, Loo CK, Chim AML, Tse CH, Wong VWS.
    J Viral Hepat; 2019 Jan 20; 26(1):126-135. PubMed ID: 30187604
    [Abstract] [Full Text] [Related]

  • 25. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
    Chen X, Cao Z, Liu Y, Zhang H, Zhang Y, Ma L, Jin Y, Yu H, Ma B, Zheng Y, Wu H.
    J Gastroenterol Hepatol; 2012 Mar 20; 27(3):481-6. PubMed ID: 22098411
    [Abstract] [Full Text] [Related]

  • 26. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J, Jones J, Takeda A, Davidson P, Price A.
    Health Technol Assess; 2006 Aug 20; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [Abstract] [Full Text] [Related]

  • 27. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B.
    Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, Schuchmann M.
    J Clin Virol; 2012 May 20; 54(1):93-5. PubMed ID: 22365367
    [Abstract] [Full Text] [Related]

  • 28. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y.
    J Clin Virol; 2009 Oct 20; 46(2):117-23. PubMed ID: 19651540
    [Abstract] [Full Text] [Related]

  • 29. Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients.
    Song EY, Shin Y, Roh EY, Sue S, Park MH, Kim BH, Kim W, Yoon JH, Lee YJ, Park SJ, Jung EU, Lee JH, Myung SJ, Kim YJ, Lee HS.
    J Med Virol; 2011 Jan 20; 83(1):88-94. PubMed ID: 21108343
    [Abstract] [Full Text] [Related]

  • 30. [Changes in lymphocyte surface expression of CD8 and CD38 molecules in peripheral blood of inactive HBsAg carriers following pegylated interferon a-2a therapy].
    Yu HB, Ma LN, Liu YL, Hua W, He ZM, Lu JF, Chen XY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec 20; 21(12):895-8. PubMed ID: 24636289
    [Abstract] [Full Text] [Related]

  • 31. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD, Chen XF, Zhou Y, Chen XP.
    J Viral Hepat; 2017 Nov 20; 24 Suppl 1():36-42. PubMed ID: 29082651
    [Abstract] [Full Text] [Related]

  • 32. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z, Li X, Shi C, Zhang M, Chen R, Wu W, Hou Q, Ke W, Fan T, Wen Z, Hao X, Qu N.
    Mol Med Rep; 2015 Jan 20; 11(1):427-33. PubMed ID: 25324041
    [Abstract] [Full Text] [Related]

  • 33. [A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].
    Huang ZL, Zhao ZX, Deng H, Zhang YF, Lu CR, Gao ZL.
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun 20; 18(6):419-22. PubMed ID: 20587310
    [Abstract] [Full Text] [Related]

  • 34. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
    Wang ML, Liao J, Wei B, Zhang DM, He M, Tao MC, Chen EQ, Tang H.
    Infect Dis (Lond); 2018 Jul 20; 50(7):522-530. PubMed ID: 29463147
    [Abstract] [Full Text] [Related]

  • 35. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P.
    Hepatology; 2009 Apr 20; 49(4):1151-7. PubMed ID: 19115222
    [Abstract] [Full Text] [Related]

  • 36. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.
    Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.
    Antivir Ther; 2018 Apr 20; 23(8):639-646. PubMed ID: 29856363
    [Abstract] [Full Text] [Related]

  • 37. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.
    Arends P, Rijckborst V, Zondervan PE, Buster E, Cakaloglu Y, Ferenci P, Tabak F, Akarca US, Simon K, Sonneveld MJ, Hansen BE, Janssen HL.
    J Viral Hepat; 2014 Dec 20; 21(12):897-904. PubMed ID: 24444353
    [Abstract] [Full Text] [Related]

  • 38. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
    Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Li ZZ, Hua WH, Song SJ, Xie Y.
    Chin Med J (Engl); 2017 Mar 05; 130(5):559-565. PubMed ID: 28229987
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
    Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P.
    J Hepatol; 2009 Jun 05; 50(6):1084-92. PubMed ID: 19376603
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.